Hedyotis

Hedyotis: A Comprehensive Reference

1. Identity and Botanical Classification

Genus and Principal Species

Hedyotis is a large genus of flowering plants in the family Rubiaceae (the madder or coffee family). In traditional medicine, over 20 Hedyotis species have been used for treatment of diseases and in healing practices; the most prominent among these are Hedyotis diffusa and Hedyotis corymbosa, which are active principles in several Chinese remedies such as bai hua she she cao, peh hue juwa chi cao, and feibao syrup. Phytochemical investigation of Hedyotis species was first published in 1933, upon examining the active components of the medicinal plant H. auricularia; since then, over 50 novel compounds have been isolated from various members of the genus.

Hedyotis diffusa Willd. — Primary Medicinal Species

Hedyotis diffusa Willd. (also known as Hedyotis diffusa herba and Oldenlandia diffusa; Chinese: 白花蛇舌草, Bái Huā Shé Shé Cǎo) is a traditional Chinese herb medicine historically used for thousands of years, traditionally employed in heat-clearing, detoxification, and removal of blood stasis. The Chinese name translates literally as "white-flowered snake-tongue herb," referring to the aerial parts of Hedyotis diffusa (synonymous with Oldenlandia diffusa). It is a plant commonly used as folk medicine and distributed in southern provinces of China.

It grows mainly in the southeastern provinces of China and is found at low altitudes in fields with moist soil; it gets its name in part due to its leaves, which are thin and shaped like a snake's tongue. The plant is not drought tolerant and prefers a warm and humid environment, often growing in wet fields, roadsides, riversides, and grasslands; it is distributed in China, Japan, India, and Nepal.

Hedyotis corymbosa — The Second Significant Species

Oldenlandia corymbosa (L.) Lam., synonymous with Hedyotis corymbosa (L.) Lam., is a weedy annual herb found throughout India. Hedyotis corymbosa is an erect or prostrate, sparsely branched annual plant with stems up to 40 cm long that sometimes root at the nodes. A key practical concern in commerce is that H. corymbosa has commonly become an adulterant of H. diffusa Willd., necessitating specialized molecular detection methods for quality control.

Nomenclatural Notes

The genus Hedyotis and the older genus Oldenlandia are closely related and their circumscriptions have shifted across botanical revisions; many species have been published under both names and may appear interchangeably in the literature. Synonyms and alternate names in commerce include: bai hua she she cao, Hedyotis, Hedyotis whole plant extract, Oldenlandia, Oldenlandia diffusa herb extract, and spreading hedyotis.

2. Natural Source and Common Forms / Preparations

Hedyotis diffusa is the dried whole herb of Hedyotis diffusa Willd. Every summer and autumn, the plant is gathered, impurities are removed, it is washed with water, dried in the sun, cut into segments, and made into traditional Chinese herbal medicine.

The herb is prepared and consumed in several forms:

• Decoction (water extract): The traditional method of preparation involves boiling 30 to 60 grams of the dried plant to create a decoction.
• Dried cut herb: Used for home brewing of teas and decoctions; collected in summer and autumn.
• Powders, liquid extracts, and encapsulated supplements: Modern preparations offer convenience and more standardized concentrations of the plant's compounds.
• Compound granules and patent medicines: There are about 50 kinds of Chinese medicine prescriptions containing Bai Hua She She Cao, such as Shuang Hu Qing Gan Granule, Yangzheng Xiaoji capsule, and Huahong Capsule.
• Pharmaceutical-grade granules: The herb belongs to the category of herbs that clear heat and resolve toxicity in the Chinese Materia Medica and has gained prominence in modern Chinese herbal medicine as a key adjunctive herb in integrative oncology and chronic inflammatory presentations.

3. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

Unlike many ancient TCM herbs, Bai Hua She She Cao has a relatively recent history of use, with limited mentions in early herbal texts; its earliest documented use appears in the Qing Dynasty's Compendium of Materia Medica Supplement by Zhao Xuemin, who noted its effectiveness in treating sores caused by syphilis. Over time, its applications expanded through folk and regional herbal practices, particularly for its heat-clearing, detoxifying, and anti-tumor properties.

The plant first appeared formally in Chinese pharmaceutical literature in the Guǎng Xī Zhōng Yào Zhì (List of traditional Chinese medicine resources in Guangxi) in 1959 AD. According to the Chinese Pharmacopoeia, the medicinal nature of Bai Hua She She Cao is relatively cold, with a slightly bitter and sweet taste, and it has a certain therapeutic effect on the pathological changes of the stomach, large intestine, and small intestine meridians.

The herb of H. diffusa has the traditional effects of clearing heat and detoxifying, relieving pain and dispelling masses, diuresis, and dehumidification; it is mainly used for treating lung heat, asthma and cough, gastroenteritis, appendicitis, urinary system infection, throat swelling and pain, intestinal carbuncle sore, dysentery, and malignant tumors. Its most famous traditional use is in the treatment of snake bites, particularly the bite of the agkistrodon (a type of pit viper); oldenlandia has also been employed to treat sores and carbuncles on the skin, appendicitis, sore throats, and urinary tract infections.

According to the literature, it has been used as a major component in several Chinese medicine formulas to treat cancer, as well as to provide a benefit against the adverse reactions of chemotherapy. In recent years within TCM practice, it has been widely used to clear heat and remove toxins, drain dampness, treat skin ulcers, chronic hepatitis B, non-lymphocytic leukemia, pneumonia, cholecystitis, simple appendicitis, pelvic inflammation, rheumatoid arthritis, chronic nephritis, recurrent stomatitis, acne, snake bite, and a variety of cancers.

Ayurvedic and South/Southeast Asian Traditional Use

Hedyotis corymbosa, also known as Oldenlandia corymbosa, has a well-documented history of use in traditional medicine systems, particularly in Ayurveda, Siddha, and traditional Chinese medicine; in these traditions, the plant is often used for its purported properties as an antipyretic, anti-inflammatory, and general health tonic. Chinese folk medicine describes the plant as treating skin sores, ulcers, sore throat, bronchitis, gynecologic infections, and pelvic inflammatory diseases.

H. corymbosa's traditional uses extend to ailments like appendicitis, hepatitis, pulmonary infections, gallbladder disorders, urinary tract infections, soft tissue inflammation, and snakebite management. In Cambodia, Laos, Vietnam, and India, Hedyotis corymbosa is used in traditional medicine for worms (antiparasitic applications).

4. Key Constituents and Active Compounds

Up to 171 compounds have been reported from H. diffusa, including 32 iridoids, 26 flavonoids, 24 anthraquinones, 26 phenolics and their derivatives, 50 volatile oils, and 13 miscellaneous compounds. More recent analyses have extended this count: according to the literature, more than 180 compounds have been characterized from H. diffusa, including iridoids, flavonoids, anthraquinones, phenolics, volatile oils, and polysaccharides.

Iridoids

Iridoids are among the most important components in H. diffusa with various bioactivities, such as antioxidant, neuroprotective, and anti-inflammatory effects; to date, thirty-two iridoids and their iridoid glucosides have been isolated and identified from H. diffusa. Key iridoids identified include asperuloside, asperulosidic acid, desacetyl asperulosidic acid, scandoside methyl ester, and E-6-O-p-coumaroyl scandoside methyl ester. Previous studies have found that iridoids in H. diffusa play an important role in its anti-inflammatory activity; asperuloside (ASP), asperulosidic acid (ASPA), desacetyl asperulosidic acid (DAA), scandoside methyl ester (SME), and E-6-O-p-coumaroyl scandoside methyl ester (CSME) are among the principal iridoid constituents studied.

Flavonoids

Twenty-six flavonoids have been identified in H. diffusa. Among reported compounds are quercetin and kaempferol, both of which are among the most frequently cited bioactive flavonoids of the plant. Network pharmacology analyses show that quercetin (degree = 94) and ursolic acid (degree = 50) are the most critical components in HDW by target connectivity.

Anthraquinones

Identified anthraquinones include 2-hydroxy-3-methylanthraquinone, 2,6-dihydroxy-3-methyl-4-methoxyanthraquinone, and related compounds. Seven new anthraquinones with rare 2-isopropyldihydrofuran and 2,2-dimethylpyrano moieties, together with thirty-four known compounds, have been isolated from extracts of the whole plant.

Triterpenoids

Identified triterpenes from H. diffusa include arborinone, isoarborinol, oleanolic acid, and ursolic acid. The main antitumor components in H. diffusa are considered to be ursolic acid and oleanolic acid; the antitumor mechanism of ursolic acid involves inhibiting the growth of breast and colon cancer cell lines by triggering apoptosis, cell cycle arrest, and anti-metastatic and anti-angiogenic properties through various molecular targets and signaling pathways.

Polysaccharides

The isolation, purification, structural characteristics, pharmacological activities, and combined actions of Hedyotis diffusa polysaccharides have been the subject of dedicated review literature. Total flavonoids, total polysaccharides, and triterpenoids in Hedyotis diffusa Willd. have been shown to have marked tumor inhibitory activities.

Phenolics and Other Constituents

Additional isolated compounds include p-coumaric acid, methyl-p-coumarate, 2-formyl-5-hydroxymethylfuran, β-sitosterol, and daucosterol. Quantitative markers used for quality control of H. diffusa include triterpenes (ursolic acid and oleanolic acid), iridoids (geniposidic acid, deacetyl asperulosidic acid methyl ester, asperulosidic acid, and asperuloside), phenolic acids (p-coumaric acid and ferulic acid), and flavonoids (quercetin, rutin, quercetin-3-O-β-D-glucopyranoside, kaempferol, and kaempferol-3-O-β-D-glucopyranoside).

5. Mechanisms of Action

Anti-inflammatory Mechanisms

Iridoids asperuloside (ASP) and asperulosidic acid (ASPA) significantly decrease the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), in parallel with inhibition of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α, and IL-6 mRNA expression in LPS-induced RAW 264.7 macrophages. Specific iridoid constituents — scandoside, asperuloside, and asperulosidic acid — exert an anti-inflammatory effect on LPS-induced RAW 264.7 macrophages by suppressing the NF-κB and MAPK signaling pathways.

Rare substituted anthraquinones from H. diffusa display potent inhibitory activity, with IC₅₀ values ranging from 0.15 ± 0.01 to 5.52 ± 1.59 µM, on fMLP/CB-induced superoxide anion generation and elastase release cellular models.

Anticancer Mechanisms

A total of 58 different kinds of active antitumor components have been identified from HDW, including iridoids, flavonoids, flavonol glycosides, anthraquinones, phenolic acids and their derivatives, sterols, and volatile oils; their antitumor activities include inhibition of tumor cell proliferation, induction of tumor cell apoptosis and tumor angiogenesis inhibition, regulation of the host immune response, anti-inflammatory and antioxidant effects, and protective autophagy.

Hedyotis diffusa can inhibit the phosphorylation of Signal Transducer and Activator of Transcription 3 (STAT3), thereby promoting the apoptosis of tumor cells and inhibiting the proliferation of tumor cells to achieve a curative effect in treating colon cancer. Ethanol extracts of HDW (EEHDW) can induce apoptosis via a mitochondria-dependent pathway in human colon carcinoma HT-29 cells; treatment with EEHDW also inhibits CRC growth in vivo via inhibition of the STAT3 signaling pathway and suppresses tumor angiogenesis via the hedgehog signaling pathway.

Western blot and RT-PCR analyses in HepG2 hepatocellular carcinoma cells treated with DMQ (1,3-dihydroxy-2-methylanthraquinone) and the ethyl acetate fraction of H. diffusa showed upregulation of Bax, p53, Fas, FasL, p21, and cytoplasmic cytochrome C, while Bcl-2, mitochondrial cytochrome C, cyclin E, and CDK2 were downregulated in a dose-dependent manner.

Functional enrichment analysis indicates that HDW probably produces therapeutic effects against gastric cancer by synergistically regulating many biological pathways, such as nucleotide excision repair, apoptosis, cell cycle, PI3K/AKT/mTOR signaling pathway, VEGF signaling pathway, and Ras signaling pathway.

HDW plus Scutellaria barbata inhibited bladder cancer cell growth and clone formation in a dose-dependent and time-dependent manner; it also induced cell apoptosis through decreasing Akt activation and reducing the expression of antiapoptotic proteins Bcl-2 and Mcl-1.

Immunomodulatory Mechanisms

Addition of H. diffusa affects the levels of cell markers (CD3, CD11b, and CD19) in white blood cells, enhances macrophage phagocytosis, and increases the cytotoxic activities of NK cells in normal Balb/c mice; taken together, these studies show that H. diffusa has anti-inflammatory, anti-cancer, and immunomodulatory activities.

Hepatoprotective Mechanisms

Water extract of H. diffusa Willd. may have hepatoprotective activity; current scientific evidence supports the view that antioxidant compounds can reduce tissue damage caused by oxidative stress through reducing reactive oxygen species (ROS) levels.

6. Scientific Evidence by Area of Use

6.1 Oncology / Anticancer Activity

Overview of evidence strength: The body of oncology research on H. diffusa is extensive but predominantly preclinical (in vitro cell-line studies and animal xenograft models). Robust, prospective human clinical trials are currently lacking.

In recent years, HDW extracts have been proved to demonstrate excellent anti-colorectal cancer effects and have been widely used in clinical practices. HDW, a Chinese herb medicine, has received great attention in the past two decades and has been well documented in clinics for antitumor activity in a variety of human cancers.

Colorectal Cancer

Previous studies have demonstrated that HDW exhibits potent anticancer activity in models of colorectal cancer (CRC); aggressive forms of CRC exhibit resistance to widely used chemotherapeutic drugs including 5-fluorouracil (5-FU); the mechanism of action and potency of ethanol extracts of HDW (EEHDW) have been investigated against a multidrug-resistant CRC HCT-8/5-FU cell line. The IC₅₀ values of HDW constituents in colorectal cancer cell lines were close to those of chemical drugs such as paclitaxel and 5-FU, and had no inhibitory effect on normal cell lines (IC₅₀ > 200 µM) in vitro. These findings are in vitro and require further in vivo and human validation.

Hepatocellular Carcinoma (HCC)

HDW has been widely used as an adjuvant therapy against various cancers including hepatocellular carcinoma; the underlying anticancer mechanisms are yet to be fully elucidated, and the efficacy and safety of HDW combined with low-dose 5-fluorouracil (5-FU) have been investigated in preclinical models. Pre-treatment with caspase-8 inhibitor or caspase-9 inhibitor attenuated the growth-inhibitory and apoptosis-inducing effects of DMQ and the H. diffusa ethyl acetate fraction on HepG2 cells, suggesting that HDW-derived compounds show potential anticancer effects mediated through caspase-dependent pathways. Evidence remains at the in vitro and animal level.

Lung Cancer

Research has shown that H. diffusa can inhibit the proliferation of H1975 (NSCLC) cells, and total triterpenes extracted from H. diffusa (TTH) have been investigated for their effects on migration, proliferation, and apoptosis of H1975 cells. Investigation of the aqueous extract from Hedyotis diffusa plus Scutellaria barbata at equal weight ratio (HDSB11) showed the lowest IC₅₀ in inhibiting LLC (murine NSCLC) cell proliferation at 0.43 mg/mL; HDSB11 also effectively suppressed colony formation and induced cell apoptosis. Evidence is preclinical (cell line and murine model).

Prostate Cancer

The usage of HDW as an anti-tumor herb to treat different types of cancer, including prostate cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer, and ovarian cancer, has been supported by research. A network pharmacology study in Biomolecules (2019) investigated the multi-target pharmacological mechanism of HDW acting on prostate cancer. All evidence is computational and in vitro.

Cervical Cancer

In clinical practice, HDW has pharmacological effects in treating cervical cancer, but its components are complex and the mechanism is still under active investigation; network pharmacology analysis identified key targets and their effective components, notably beta-sitosterol and quercetin, as playing a therapeutic role. HDW has exhibited potential in suppressing the progression of liver cancer, colorectal cancer, and lung cancer, though its application in treating cervical cancer specifically has been limited.

Summary — Oncology Evidence: HDW has demonstrated significant anticancer potential in preclinical studies, with its ability to inhibit tumor growth, induce apoptosis, suppress metastasis, and modulate the immune response; its low toxicity and mechanisms of action position it as a promising complementary therapy to conventional cancer treatments; however, while preclinical studies highlight its efficacy, more investigation is required to confirm these results in clinical settings.

6.2 Anti-Inflammatory Activity

Generally, H. diffusa is used as a single herb or in Chinese traditional medicine prescriptions for the treatment of nephritis, arthritis, bronchitis, and appendicitis; modern pharmacological studies have confirmed that H. diffusa possesses multiple effects, including anti-inflammatory, anti-cancer, neuroprotective, hepatoprotective, and immunomodulating activities.

In a complete Freund's adjuvant (CFA)-induced arthritis model in rats, 12 days of oral treatment with HDW extract ursolic acid at 50 mg/kg/day was demonstrated to suppress paw swelling, plasma PGE₂ production, spinal Fos expression, and arthritis-induced mechanical and thermal hyperalgesia. This is a preclinical (animal) study. Human clinical evidence for anti-inflammatory endpoints is not yet established.

6.3 Rheumatoid Arthritis

HDW and its main components have been widely used to treat a variety of tumors and inflammatory diseases; a study utilizing network pharmacology, microarray data analysis, and molecular docking predicted the key active ingredients and mechanisms of HDW against RA, identifying 11 active ingredients in HDW and 180 potential anti-RA targets. The ingredient–targets–RA network showed that stigmasterol, beta-sitosterol, quercetin, kaempferol, and 2-methoxy-3-methyl-9,10-anthraquinone were key components for RA treatment; KEGG pathway results revealed that the 180 potential targets were predominantly in inflammatory-related pathways, including AGE-RAGE, TNF, IL-17, and PI3K-Akt signaling pathways. Evidence is network pharmacology and requires experimental validation in humans.

6.4 Hepatoprotective Activity

Application of a decoction of H. diffusa in a lipopolysaccharide/galactosamine (LPS/GALN)-induced acute liver injury mouse model delayed the incidence of death and increased the survival rate by twofold compared with saline control. A water extract of H. diffusa has also been studied in vitro in human hepatocyte LO2 cells for protection against oxidative stress-induced cytotoxicity, with preliminary hepatoprotective findings reported. All hepatoprotective evidence is preclinical (cell-based or animal).

6.5 Renal and Autoimmune Conditions

Investigation of the anti-inflammatory effect of H. diffusa extract in renal inflammation, specifically evaluating which constituents are absorbed into blood to produce the anti-inflammatory effect, has been a focus of preclinical research; clarifying these bioactive constituents plays a key role in rational clinical use of the plant. Pharmacological studies show that HDW has antioxidative, anti-inflammatory, neuroprotective, and immunomodulating effects; the HDW extract had a protective effect against renal inflammation induced by LPS in animal models. A 2022 Frontiers in Immunology study investigated the protective capability of HDW on lupus nephritis via attenuation of IL-17 expression in MRL/lpr mice — an animal model of systemic lupus erythematosus. Human clinical data are absent.

6.6 Neuroprotective Activity

Isolated constituents from Hedyotis diffusa have exhibited significant neuroprotective activity in primary cultures of rat cortical cells damaged by L-glutamate. In vitro and in vivo studies show phytochemicals and plant extracts to exhibit neuroprotective effects. Evidence is currently limited to cell and animal models.

6.7 Antimicrobial and Antiparasitic Activity

Extract of H. corymbosa was lethal for Plasmodium falciparum with an IC₅₀ value of 10.8 µg/mL in vitro. The plant produces iridoids, including 6β-hydroxygeniposide; its use in four different countries for worms suggests that strong anthelmintic principles await further discovery. These findings are in vitro or derived from ethnobotanical correlations rather than controlled clinical trials.

6.8 Immunomodulatory Activity

An in vivo study investigated whether ethanol extract of H. diffusa Willd (EEHDW) could affect immune responses in normal murine cells; normal BALB/c mice were orally treated with EEHDW at 0, 16, 32, and 64 mg/kg or 32 mg/kg by i.p. for 3 weeks, then weighed, with blood, liver, and spleen samples collected; results indicated that EEHDW did not significantly affect body and liver weight. EEHDW significantly increased spleen weight by intraperitoneal treatment compared to control groups, suggesting immune organ effects. All data are animal-based.

7. Body Systems and Health Areas Associated with Hedyotis

• Oncology / Immune: HDW has been widely studied as a potential therapeutic drug for treatment of malignant tumors of the breast, stomach, colon, rectum, cervix, and ovary.
• Inflammation and Autoimmunity: HDW has been used in the treatment of inflammation-related diseases, including urinary tract infection, colitis, tonsillitis, appendicitis, pharyngitis, hepatitis, dysentery, diarrhea, and snake bites.
• Hepatic system: Anti-inflammatory and hepatoprotective effects observed in preclinical models of acute liver injury and hepatocellular carcinoma.
• Renal system: Preclinical evidence for protection in LPS-induced renal inflammation and lupus nephritis animal models.
• Nervous system: Neuroprotective constituents identified in cortical cell culture models.
• Musculoskeletal system: H. diffusa is used as a single herb or in Chinese traditional medicine prescriptions for the treatment of nephritis, arthritis, bronchitis, and appendicitis.
• Urinary and digestive systems: Traditional uses for urinary tract infection, appendicitis, and gastrointestinal infections.

8. Dosage Forms and Reported Dosages

The traditional method of preparation involves boiling 30 to 60 grams of the dried plant to create a decoction; dosages can vary based on the condition, the form of the herb used, and a practitioner's guidance.

In documented preclinical studies, the following dosages have been reported:

• Oral treatment with ursolic acid derived from HDW at 50 mg/kg/day for 12 days was used in a rat arthritis model.
• Normal BALB/c mice were treated with EEHDW orally at 0, 16, 32, and 64 mg/kg, or 32 mg/kg intraperitoneally, for 3 weeks in an immunomodulatory study.
• An IC₅₀ of 0.43 mg/mL for aqueous extract of H. diffusa plus Scutellaria barbata (1:1) was reported for LLC cell proliferation inhibition in vitro.

The Compound Granules of Hedyotis diffusa (CGHD) is a hospital preparation composed of three herbs — Hedyotis diffusa Willd, Smilax china L., and Solanum lyratum Thunb — the safety of which has been evaluated by acute toxicity and long-term toxicity experiments. No standardized human dosage has been established through controlled clinical trials.

9. Safety Considerations and Interactions

Toxicity Profile

Results of acute toxicity and long-term toxicity studies of Compound Granules of Hedyotis diffusa (CGHD) showed that CGHD was nontoxic or had low toxicity, providing a scientific basis for clinical application, determining the appropriate clinical dose, and monitoring clinical toxicity.

Hedyotis diffusa is considered to have low toxicity when used at clinical doses, often cited as 30–60 grams per day in decoctions; however, side effects can occur, and comprehensive safety data are lacking for long-term use, pregnancy, and lactation.

Potential for Organ Toxicity at High Doses

Long-term consumption, particularly in high doses, may lead to liver or kidney function alterations, although comprehensive human data are limited; furthermore, Hedyotis diffusa may interact with conventional chemotherapeutic agents by modulating cytochrome P450 enzyme activity, potentially affecting drug metabolism and efficacy; these aspects highlight the need for cautious integration with standard cancer therapies and underscore the importance of further pharmacokinetic and toxicity studies.

Drug Interaction Potential

Hedyotis diffusa may interact with conventional chemotherapeutic agents by modulating cytochrome P450 enzyme activity, potentially affecting drug metabolism and efficacy. This is a theoretical concern based on in vitro data; human pharmacokinetic interaction studies have not been reported.

Species Adulteration Risk

There is increasing demand for Hedyotis diffusa Willd. due to its effectiveness in treating hepatitis and malignant tumors; Hedyotis corymbosa (L.) Lam. has commonly become an adulterant of H. diffusa Willd. Specialized molecular methods have been developed to detect this adulteration in herbal preparations, underscoring the importance of verified-source products.

Absence of Human Clinical Safety Data

The effects of Hedyotis diffusa in humans require more thorough investigation, as human clinical trials are limited. Although a series of methods have been established for the quality control of H. diffusa, a feasible and reliable approach is still needed in consideration of its botanical origin, collecting time, and bioactive effects; meanwhile, more pharmacokinetics research is needed to illustrate the characteristics of H. diffusa in vivo.

Traditional Contraindications

Within traditional Chinese medicine, Bai Hua She She Cao is classified as cold in nature. Traditional practice notes contraindications in conditions involving cold-type cough (wind-cold or phlegm patterns) and diarrhea. Pregnancy and lactation contraindications are noted in traditional sources, though no human pharmacovigilance data are available to quantify these risks.

References

• Niu Y, Meng QX. Chemical and preclinical studies on Hedyotis diffusa with anticancer potential. J Asian Nat Prod Res. 2013;15(5):550-65. PubMed PMID: 23600735
• Chen R, He J, Tong X, Tang L, Liu M. The Hedyotis diffusa Willd. (Rubiaceae): A Review on Phytochemistry, Pharmacology, Quality Control and Pharmacokinetics. Molecules. 2016;21(6):710. PMC6273454
• Chemical Constituents of Hedyotis diffusa and Their Anti-Inflammatory Bioactivities. PMC8868389
• Mechanism of Hedyotis Diffusa in the Treatment of Cervical Cancer. PMC8715005
• Molecular Mechanism of Anti-Colorectal Cancer Effect of Hedyotis diffusa Willd and Its Extracts. PMC9201484
• Inhibitory effects of total triterpenoids isolated from Hedyotis diffusa Willd on H1975 cells. PMC9515512
• Hedyotis diffusa Willd overcomes 5-fluorouracil resistance in human colorectal cancer HCT-8/5-FU cells. PMC4665806
• Network Pharmacology-Based Approach to Investigate the Mechanisms of Hedyotis diffusa Willd. in the Treatment of Gastric Cancer. PMC5954954
• Hedyotis diffusa Willd. extract suppresses proliferation and induces apoptosis via IL-6-inducible STAT3 pathway inactivation in human colorectal cancer cells. PMC4356405
• Hedyotis diffusa plus Scutellaria barbata Induce Bladder Cancer Cell Apoptosis by Inhibiting Akt Signaling Pathway. PMC4773537
• Hedyotis diffusa plus Scutellaria barbata Suppress the Growth of Non-Small-Cell Lung Cancer via NLRP3/NF-κB/MAPK Signaling Pathways. PMC8233093
• Network pharmacology and experimental validation to identify the potential mechanism of Hedyotis diffusa Willd against rheumatoid arthritis. PMC9877023 / Scientific Reports 2023
• Metabolic regulations of a decoction of Hedyotis diffusa in acute liver injury of mouse models. PMC5738817
• The Antitumor Constituents from Hedyotis Diffusa Willd. PMC6150003
• Anticancer Effects of 1,3-Dihydroxy-2-Methylanthraquinone and the Ethyl Acetate Fraction of Hedyotis Diffusa Willd against HepG2 Carcinoma Cells. PMC4827846
• Asperuloside and Asperulosidic Acid Exert an Anti-Inflammatory Effect via Suppression of NF-κB and MAPK Signaling Pathways. PMC6073666
• Investigating the Multi-Target Pharmacological Mechanism of Hedyotis diffusa Willd Acting on Prostate Cancer: A Network Pharmacology Approach. PMC6843553
• Ethanol Extract of Hedyotis diffusa Willd Affects Immune Responses in Normal Balb/c Mice In Vivo. In Vivo 2015;29(4).
• Chemical Profiles and Protective Effect of Hedyotis diffusa Willd in Lipopolysaccharide-Induced Renal Inflammation Mice. PMC4661879
• Li Y et al. The protective capability of Hedyotis diffusa Willd on lupus nephritis by attenuating the IL-17 expression in MRL/lpr mice. Front Immunol. 2022;13:943827.
• Antitumor potential of Hedyotis diffusa Willd: A systematic review of bioactive constituents and underlying molecular mechanisms. Biomedicine & Pharmacotherapy. 2020;130:110735.
• Toxicity study of compound granules of Hedyotis diffusa: Acute toxicity and long-term toxicity. Journal of Ethnopharmacology. 2023.
• Neuroprotective Constituents from Hedyotis diffusa. Journal of Natural Products.
• Hedyotis — an overview. ScienceDirect Topics.
• Hedyotis. Wikipedia (for genus-level and ethnobotanical overview).
• Wang Y et al. Detection of Hedyotis corymbosa (L.) Lam. in traditional Chinese medicine Hedyotis diffusa Willd. with the Proofman-LMTIA method. Pharmacia. 2025;72:1–9.
• Oldenlandia corymbosa: A Phytopharmacological review. ResearchGate / Journal of Pharmacognosy and Phytochemistry.
• Chen R et al. The Hedyotis diffusa Willd. (Rubiaceae): A Review. Molecules. 2016. (Semantic Scholar / full text PDF)
• Phytochemicals, Pathways, Mechanisms and Clinical Applications: A Comprehensive review on Hedyotis diffusa (Bai Hua She She Cao) in Cancer Management. Biomedical and Pharmacology Journal. 2025.
• NIH Office of Dietary Supplements — Dietary Supplement Label Database: Bai Hua She She Cao extract.
• Molecular mechanism of the treatment of lung adenocarcinoma by Hedyotis Diffusa: an integrative study with real-world clinical data and experimental validation. Frontiers in Pharmacology. 2024.